摘要
随着二代基因检测(next generation sequencing,NGS)技术的快速发展及广泛应用,多种共突变基因被我们发现。许多研究表明,共突变在表皮生长因子受体(epidermal growth factor receptor,EGFR)突变型非小细胞肺癌(non-small cell lung cancer,NSCLC)中对EGFR酪氨酸激酶抑制剂(EGFR tyrosine kinase inhibitor,EGFR-TKI)的反应和耐药起着重要作用。其中,TP53作为EGFR突变型NSCLC最常见的共突变基因,已被证明是一代、二代及三代EGFRTKIs治疗预后差的重要因素,如何为EGFR-TP53共突变的晚期NSCLC患者选择最佳的治疗策略,目前仍在探索中。本文就近年来关于晚期NSCLC患者EGFR-TP53共突变的研究进展作一综述。
With the rapid development and wide application of next generation sequencing(NGS) technology,a series of researches have revealed that concurrent genetic alterations play an important role in the response and resistance of epidermal growth factor receptor(EGFR)-mutant NSCLC to EGFR-tyrosine kinase inhibitor(TKI).Besides,TP53 mutation is the most common co-mutation gene in EGFR-mutant NSCLC,which has been proved to confer a worse prognosis in EGFRmutated patients treated with first,second and third generation of EGFR-TKIs.Currently,it is still being explored how to select the best treatment strategies for patients with concomitant presence of TP53 mutation in EGFR-mutant NSCLC.Here,we review the literature on recent research progress of TP53 concurrent mutation in EGFR-mutant advanced NSCLC.
作者
王蓉
潘思思
宋霞
Rong WANG;Sisi PAN;Xia SONG(The Second Department of Respiratory,Shanxi Provincial Cancer Hospital,Taiyuan 030000,China;The Second Clinical Medical College of Shanxi Medical University,Taiyuan 030000,China)
出处
《中国肺癌杂志》
CAS
CSCD
北大核心
2022年第3期174-182,共9页
Chinese Journal of Lung Cancer
基金
吴阶平医学基金会临床科研专项基金(No.320.6750.2020-19-35)资助。
关键词
肺肿瘤
TP53
表皮生长因子受体
共突变
治疗
Lung neoplasms
TP53
Epidermal growth factor receptor
Co-mutation
Therapy
